Myasthenia Gravis and Related Disorders
暂无分享,去创建一个
[1] A. Vincent,et al. IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG , 2017, Neurology: Neuroimmunology & Neuroinflammation.
[2] T. Keil,et al. CD4+ FoxP3+ T regulatory cell subsets in myasthenia gravis patients. , 2017, Clinical immunology.
[3] Qiang Sun,et al. Regulatory B Cells in Seropositive Myasthenia Gravis versus Healthy Controls , 2017, Front. Neurol..
[4] L. Hobson‐Webb,et al. B10 Cell Frequencies and Suppressive Capacity in Myasthenia Gravis Are Associated with Disease Severity , 2017, Front. Neurol..
[5] P. van Damme,et al. IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients. , 2017, Journal of autoimmunity.
[6] F. Shi,et al. Augmentation of Circulating Follicular Helper T Cells and Their Impact on Autoreactive B Cells in Myasthenia Gravis , 2016, The Journal of Immunology.
[7] Jiayin Lu,et al. Imbalance of circulating CD4+CXCR5+FOXP3+ Tfr-like cells and CD4+CXCR5+FOXP3− Tfh-like cells in myasthenia gravis , 2016, Neuroscience Letters.
[8] R. Rojas-García,et al. Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin. , 2016, JAMA neurology.
[9] B. Soliven,et al. Impaired regulatory B cells in myasthenia gravis , 2016, Journal of Neuroimmunology.
[10] A. Marx,et al. Randomized Trial of Thymectomy in Myasthenia Gravis. , 2016, The New England journal of medicine.
[11] M. Ticchioni,et al. Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis , 2016, Journal of Neuroimmunology.
[12] E. Zwet,et al. Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity , 2016, Journal of Neuroimmunology.
[13] J. Lemos,et al. Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis. , 2015, JAMA neurology.
[14] L. Mei,et al. Flow Cytofluorimetric Analysis of Anti-LRP4 (LDL Receptor-Related Protein 4) Autoantibodies in Italian Patients with Myasthenia Gravis , 2015, PloS one.
[15] K. Kleopa,et al. MuSK autoantibodies in myasthenia gravis detected by cell based assay — A multinational study , 2015, Journal of Neuroimmunology.
[16] J. Maessen,et al. Robotic thymectomy in patients with myasthenia gravis: neurological and surgical outcomes. , 2015, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[17] Jacqueline A Palace,et al. Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis. , 2015, JAMA neurology.
[18] V. Damato,et al. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis , 2015, Journal of Neurology.
[19] J. Howard,et al. Characterization of B cells in muscle-specific kinase antibody myasthenia gravis , 2015, Neurology: Neuroimmunology & Neuroinflammation.
[20] D. Beeson,et al. Collagen Q – A potential target for autoantibodies in myasthenia gravis , 2015, Journal of Neurological Sciences.
[21] N. Gilhus,et al. Repeated Acetylcholine Receptor Antibody-Concentrations and Association to Clinical Myasthenia Gravis Development , 2014, PloS one.
[22] R. Balice-Gordon,et al. Cortactin autoantibodies in myasthenia gravis. , 2014, Autoimmunity reviews.
[23] K. Kleopa,et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. , 2014, Journal of autoimmunity.
[24] P. Miossec,et al. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. , 2014, Autoimmunity reviews.
[25] Li Yang,et al. Interleukin‐10 producing‐B cells and their association with responsiveness to rituximab in myasthenia gravis , 2014, Muscle & nerve.
[26] R. Lewis,et al. Autoantibodies to Agrin in Myasthenia Gravis Patients , 2014, PloS one.
[27] A. Engeland,et al. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries , 2014, Acta neurologica Scandinavica. Supplementum.
[28] Amit Bar-Or,et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases , 2014, Nature.
[29] B. Eymard,et al. Antibodies to clustered acetylcholine receptor: expanding the phenotype , 2014, European journal of neurology.
[30] G. Lauria,et al. LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients , 2013, Annals of clinical and translational neurology.
[31] H. Vrolijk,et al. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4 , 2013, Proceedings of the National Academy of Sciences.
[32] L. Mei,et al. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. , 2013, The Journal of clinical investigation.
[33] A. Vincent,et al. MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters , 2013, PloS one.
[34] M. Benatar,et al. A randomized, double‐blind, placebo‐controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis , 2013, Muscle & nerve.
[35] Gui-xian Zhao,et al. Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis , 2013, Multiple sclerosis.
[36] F. Hiepe,et al. Pathogenic Long-Lived Plasma Cells and Their Survival Niches in Autoimmunity, Malignancy, and Allergy , 2012, The Journal of Immunology.
[37] J. Bussel,et al. Defective regulatory B-cell compartment in patients with immune thrombocytopenia. , 2012, Blood.
[38] R. Howard,et al. Clinically biphasic myasthenia gravis with both AChR and MuSK antibodies , 2012, Journal of Neurology.
[39] A. Vincent,et al. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. , 2012, Archives of neurology.
[40] D. Lacomis,et al. Characteristics of late-onset myasthenia gravis , 2012, Journal of Neurology.
[41] D. Richman,et al. Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes. , 2012, Archives of neurology.
[42] A. Vincent,et al. Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects , 2012, Experimental Neurology.
[43] J. Verschuuren,et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. , 2012, Brain : a journal of neurology.
[44] R. Lewis,et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. , 2012, Archives of neurology.
[45] B. Schoser,et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis , 2012, Journal of Neurology.
[46] A. Miyazawa,et al. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. , 2012, The American journal of pathology.
[47] A. Mussi,et al. PTPN22 and myasthenia gravis: Replication in an Italian population and meta-analysis of literature data , 2012, Neuromuscular Disorders.
[48] J. Verschuuren,et al. Long-lasting treatment effect of rituximab in MuSK myasthenia , 2012, Neurology.
[49] J. Verschuuren,et al. Lambert–Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies , 2011, The Lancet Neurology.
[50] S. Jayawant,et al. Juvenile Myasthenia Gravis: A Paediatric Perspective , 2011, Autoimmune diseases.
[51] N. Singhal,et al. Role of extracellular matrix proteins and their receptors in the development of the vertebrate neuromuscular junction , 2011, Developmental neurobiology.
[52] J. Buckner,et al. CD4+FOXP3+ T Regulatory Cells in Human Autoimmunity: More Than a Numbers Game , 2011, The Journal of Immunology.
[53] J. G. van Dijk,et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] Y. Yamanashi,et al. Autoantibodies to low‐density lipoprotein receptor–related protein 4 in myasthenia gravis , 2011, Annals of neurology.
[55] D. Campbell,et al. Phenotypical and functional specialization of FOXP3+ regulatory T cells , 2011, Nature Reviews Immunology.
[56] A. Marx,et al. Thymoma and paraneoplastic myasthenia gravis , 2010, Autoimmunity.
[57] A. Vincent,et al. Diagnostic use of autoantibodies in myasthenia gravis , 2010, Autoimmunity.
[58] D. Sanders,et al. Immunosuppressive therapies in myasthenia gravis , 2010, Autoimmunity.
[59] D. Hafler,et al. FOXP3+ regulatory T cells in the human immune system , 2010, Nature Reviews Immunology.
[60] M. Farrugia,et al. The use of rituximab in myasthenia gravis and Lambert–Eaton myasthenic syndrome , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[61] M. Pasnoor,et al. Clinical findings in MuSK‐antibody positive myasthenia gravis: A U.S. experience , 2010, Muscle & nerve.
[62] D. Isenberg,et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. , 2010, Immunity.
[63] A. Twijnstra,et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] Hulun Li,et al. Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis , 2009, Immunology.
[65] I. Sanz,et al. Novel Human Transitional B Cell Populations Revealed by B Cell Depletion Therapy1 , 2009, The Journal of Immunology.
[66] M. Marino,et al. HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5 , 2009, Neurology.
[67] H. J. Schelhaas,et al. The Lambert–Eaton myasthenic syndrome 1988–2008: A clinical picture in 97 patients , 2008, Journal of Neuroimmunology.
[68] V. Scaioli,et al. Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor , 2008, Neuromuscular Disorders.
[69] S. Servidei,et al. Response to Therapy in Myasthenia Gravis with Anti‐MuSK Antibodies , 2008, Annals of the New York Academy of Sciences.
[70] O. Gervásio,et al. Anti‐MuSK patient antibodies disrupt the mouse neuromuscular junction , 2008, Annals of neurology.
[71] A. Vincent,et al. Myasthenia Gravis Seronegative for Acetylcholine Receptor Antibodies , 2008, Annals of the New York Academy of Sciences.
[72] A. Vincent,et al. Autoimmunizing Mechanisms in Thymoma and Thymus * , 2008, Annals of the New York Academy of Sciences.
[73] P. Laforêt,et al. Severe neonatal myasthenia due to maternal anti-MuSK antibodies , 2008, Neuromuscular Disorders.
[74] A. Vincent,et al. IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis† , 2008, Brain : a journal of neurology.
[75] D. Gray,et al. Not always the bad guys: B cells as regulators of autoimmune pathology , 2008, Nature Reviews Immunology.
[76] J. Verschuuren,et al. A TRANSIENT NEONATAL MYASTHENIC SYNDROME WITH ANTI-MUSK ANTIBODIES , 2008, Neurology.
[77] A. Gure,et al. SOX1 antibodies are markers of paraneoplastic Lambert–Eaton myasthenic syndrome , 2008, Neurology.
[78] S. Fuchs,et al. Ex Vivo Generated Regulatory T Cells Modulate Experimental Autoimmune Myasthenia Gravis1 , 2008, The Journal of Immunology.
[79] Chuan-zhen Lu,et al. Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis. , 2008, Clinical immunology.
[80] R. Pirskanen,et al. Two SNPs in the promoter region of the CTLA‐4 gene affect binding of transcription factors and are associated with human myasthenia gravis , 2007, Journal of internal medicine.
[81] N. Gilhus,et al. Polygenic disease associations in thymomatous myasthenia gravis. , 2007, Archives of neurology.
[82] E. Rendina,et al. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas , 2007, Clinical and experimental immunology.
[83] X. Ke,et al. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus , 2007, Nature.
[84] W. J. Hamilton,et al. ANTI-MUSK ANTIBODY AFTER THYMECTOMY IN A PREVIOUSLY SEROPOSITIVE MYASTHENIC CHILD , 2007, Neurology.
[85] R. Caspi,et al. C57BL/6 Mice Genetically Deficient in IL-12/IL-23 and IFN-γ Are Susceptible to Experimental Autoimmune Myasthenia Gravis, Suggesting a Pathogenic Role of Non-Th1 Cells1 , 2007, The Journal of Immunology.
[86] Rob C. G. van de Ven,et al. Severely impaired neuromuscular synaptic transmission causes muscle weakness in the Cacna1a‐mutant mouse rolling Nagoya , 2007, The European journal of neuroscience.
[87] S. Ikeda,et al. Comparison of the histological and immunohistochemical features of the thymus in young- and elderly-onset myasthenia gravis without thymoma , 2007, Journal of Clinical Neuroscience.
[88] M. Mizuno,et al. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice , 2006, Clinical and experimental immunology.
[89] B. Prabhakar,et al. Suppression of Experimental Autoimmune Myasthenia Gravis by Granulocyte-Macrophage Colony-Stimulating Factor Is Associated with an Expansion of FoxP3+ Regulatory T Cells1 , 2006, The Journal of Immunology.
[90] Min Zhang,et al. Clinical and serological study of myasthenia gravis in HuBei Province, China , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[91] B. Lecky. Transient neonatal Lambert–Eaton syndrome , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[92] G. Pearse. Normal Structure, Function and Histology of the Thymus , 2006, Toxicologic pathology.
[93] A. Vincent,et al. Strong association of MuSK antibody–positive myasthenia gravis and HLA-DR14-DQ5 , 2006, Neurology.
[94] P. Matthews,et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. , 2006, Brain : a journal of neurology.
[95] Y. Abe,et al. Induction of myasthenia by immunization against muscle-specific kinase. , 2006, The Journal of clinical investigation.
[96] A. Vincent,et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis , 2005, Neurology.
[97] A. Marx,et al. Pathology of thymic tumors. , 2005, Seminars in thoracic and cardiovascular surgery.
[98] A. Marx,et al. Fewer thymic changes in MuSK antibody‐positive than in MuSK antibody‐negative MG , 2005, Annals of neurology.
[99] A. Vincent,et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody–positive myasthenia gravis , 2005, Annals of neurology.
[100] A. Saoudi,et al. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. , 2005, Blood.
[101] A. Rosenwald,et al. Selective loss of regulatory T cells in thymomas , 2004, Annals of neurology.
[102] B. Rees Smith,et al. Muscle-specific receptor tyrosine kinase autoantibodies--a new immunoprecipitation assay. , 2004, Clinica chimica acta; international journal of clinical chemistry.
[103] P. Christadoss,et al. ICOS is essential for the development of experimental autoimmune myasthenia gravis , 2004, Journal of Neuroimmunology.
[104] A. Vincent,et al. Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese , 2004, Neurology.
[105] A. Vincent,et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis , 2004, Annals of neurology.
[106] R. Pirskanen,et al. Circulating CD4+CD25+ and CD4+CD25– T Cells in Myasthenia Gravis and in Relation to Thymectomy , 2004, Scandinavian journal of immunology.
[107] P. Barzaghi,et al. Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference , 2004, EMBO reports.
[108] S. Higgs,et al. Genetic Evidence for Involvement of Classical Complement Pathway in Induction of Experimental Autoimmune Myasthenia Gravis 1 , 2003, The Journal of Immunology.
[109] P. Tonali,et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. , 2003, Brain : a journal of neurology.
[110] P. Rothwell,et al. Evidence of underdiagnosis of myasthenia gravis in older people , 2003, Journal of neurology, neurosurgery, and psychiatry.
[111] A. Vincent,et al. Clinical aspects of MuSK antibody positive seronegative MG , 2003, Neurology.
[112] H. Putter,et al. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland , 2003, Journal of Neurology.
[113] M. Wadhwa,et al. Anti‐cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon‐alpha, interferon‐omega and interleukin‐12 in patients with thymoma and/or myasthenia gravis , 2003, Clinical and experimental immunology.
[114] A. Vincent,et al. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? , 2001, Neurology.
[115] S. J. Wood,et al. Safety factor at the neuromuscular junction , 2001, Progress in Neurobiology.
[116] J. Palace,et al. Myasthenia gravis , 2001, The Lancet.
[117] P. Karachunski,et al. Absence of IFN-γ or IL-12 Has Different Effects on Experimental Myasthenia Gravis in C57BL/6 Mice1 , 2000, The Journal of Immunology.
[118] J. Lindstrom. Acetylcholine receptors and myasthenia , 2000, Muscle & nerve.
[119] P. Christadoss,et al. Animal models of myasthenia gravis. , 2000, Clinical immunology.
[120] M. Bunce,et al. A susceptibility region for myasthenia gravis extending into the HLA-class I sector telomeric to HLA-C. , 1999, Human immunology.
[121] A. Vincent,et al. Monoclonal antibodies raised against human acetylcholine receptor bind to all five subunits of the fetal isoform , 1999, Journal of Neuroimmunology.
[122] R. Van Ree,et al. Normal human immunoglobulin G4 is bispecific: it has two different antigen‐combining sites , 1999, Immunology.
[123] K. Iwasa,et al. Calcium channel peptide can cause an autoimmune-mediated model of Lambert–Eaton myasthenic syndrome in rats , 1999, Journal of the Neurological Sciences.
[124] A. Vincent,et al. Plasma from human mothers of fetuses with severe arthrogryposis multiplex congenita causes deformities in mice. , 1999, Journal of Clinical Investigation.
[125] P. Karachunski,et al. Interleukin-4 deficiency facilitates development of experimental myasthenia gravis and precludes its prevention by nasal administration of CD4+ epitope sequences of the acetylcholine receptor , 1999, Journal of Neuroimmunology.
[126] D. Beeson,et al. Early‐onset myasthenia gravis: A recurring T‐cell epitope in the adult‐specific acetylcholine receptor ε subunit presented by the susceptibility allele HLA‐DR52a , 1999, Annals of neurology.
[127] Zeng-Yu Wang,et al. Myasthenia in SCID mice grafted with myasthenic patient lymphocytes , 1999, Neurology.
[128] J. Howard,et al. TCR-Vβ Usage in the Thymus and Blood of Myasthenia Gravis Patients☆ , 1998 .
[129] P. Christadoss,et al. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. , 1998, Journal of immunology.
[130] B. He,et al. Differential requirements for CD28 and CD40 ligand in the induction of experimental autoimmune myasthenia gravis , 1998, Journal of Neuroimmunology.
[131] N. Gilhus,et al. The histomorphology of the thymus in late onset, non‐thymoma myasthenia gravis , 1998 .
[132] J. Changeux,et al. An acetylcholine receptor alpha subunit promoter confers intrathymic expression in transgenic mice. Implications for tolerance of a transgenic self-antigen and for autoreactivity in myasthenia gravis. , 1998, The Journal of clinical investigation.
[133] H. Müller-Hermelink,et al. Abnormal thymocyte development and generation of autoreactive T cells in mixed and cortical thymomas. , 1998, Laboratory investigation; a journal of technical methods and pathology.
[134] Zeng-Yu Wang,et al. CD4+ Epitope Spreading and Differential T Cell Recognition of Muscle Acetylcholine Receptor Subunits in Myasthenia Gravis a , 1998, Annals of the New York Academy of Sciences.
[135] J. Oger,et al. Rapsyn Antibodies in Myasthenia Gravis a , 1998, Annals of the New York Academy of Sciences.
[136] Zeng-Yu Wang,et al. T Cell Recognition of the Acetylcholine Receptor in Myasthenia Gravis a , 1998, Annals of the New York Academy of Sciences.
[137] N. Gilhus,et al. Titin transcripts in thymomas. , 1997, Annals of the New York Academy of Sciences.
[138] P. Christadoss,et al. Interferon γ (IFN-γ) Is Necessary for the Genesis of Acetylcholine Receptor–induced Clinical Experimental Autoimmune Myasthenia gravis in Mice , 1997, The Journal of experimental medicine.
[139] K. Iwasa,et al. Antibodies to synthetic peptides of the alA subunit of the voltage‐gated calcium channel in Lambert‐Eaton myasthenic syndrome , 1997, Neurology.
[140] Jacqueline Palace,et al. Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome , 1997, Journal of the Neurological Sciences.
[141] I. Kockum,et al. TAP polymorphisms in Swedish myasthenia gravis patients. , 1997, Tissue antigens.
[142] A. Vincent,et al. A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis , 1996, Neurology.
[143] A. Vincent,et al. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis , 1996, Journal of Neuroimmunology.
[144] P. Distefano,et al. The Receptor Tyrosine Kinase MuSK Is Required for Neuromuscular Junction Formation In Vivo , 1996, Cell.
[145] S. Nagataki,et al. Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome , 1995, Journal of the Neurological Sciences.
[146] K. Mikoshiba,et al. Thymomas express epitopes shared by the ryanodine receptor , 1995, Journal of Neuroimmunology.
[147] P. Molenaar,et al. Acetylcholine release in myasthenia gravis: Regulation at single end‐plate level , 1995, Annals of neurology.
[148] S. Huson,et al. Recurrent congenital arthrogryposis leading to a diagnosis of myasthenia gravis in an initially asymptomatic mother , 1995, Neuromuscular Disorders.
[149] E. Rieber,et al. Treatment of myasthenia gravis with anti‐CD4 antibody , 1994, Neurology.
[150] F. Somnier. Exacerbation of myasthenia gravis after removal of thymomas , 1994, Acta neurologica Scandinavica.
[151] H. Garchon,et al. Involvement of human muscle acetylcholine receptor alpha-subunit gene (CHRNA) in susceptibility to myasthenia gravis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[152] H. Garchon,et al. Association of Km3 allotype with increased serum levels of autoantibodies against muscle acetylcholine receptor in myasthenia gravis , 1994, Journal of Neuroimmunology.
[153] M. Shenoy,et al. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. , 1994, Journal of immunology.
[154] J. Newsom-Davis,et al. Heterogeneity of calcium channel autoantibodies detected using a small‐cell lung cancer line derived from a Lambert‐Eaton myasthenic syndrome patient , 1994, Neurology.
[155] C Bona,et al. Defining criteria for autoimmune diseases (Witebsky's postulates revisited) , 1993, Immunology today.
[156] A. Drosos,et al. D-penicillamine induced myasthenia gravis: clinical, serological and genetic findings. , 1993, Clinical and experimental rheumatology.
[157] C. Aimé,et al. Antibodies to thymic epithelial cells in myasthenia gravis , 1991, Journal of Neuroimmunology.
[158] V. Lennon,et al. Mouse T lymphocyte response to acetylcholine receptor determined by T cell receptor for antigen V beta gene products recognizing Mls-1a. , 1991, Journal of Immunology.
[159] P Wordsworth,et al. Critical role for the Val/Gly86 HLA-DR beta dimorphism in autoantigen presentation to human T cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[160] E. M. Adler,et al. Strategic location of calcium channels at transmitter release sites of frog neuromuscular synapses , 1990, Neuron.
[161] J. Wolinsky,et al. Immune studies in human immunodeficiency virus infection with myasthenia gravis , 1990, Neurology.
[162] G. Biesecker,et al. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. , 1989, Journal of immunology.
[163] A. Engel,et al. Lambert‐eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation , 1988, Annals of neurology.
[164] N. Murray,et al. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. , 1988, Brain : a journal of neurology.
[165] P. Whiting,et al. Antibody Heterogeneity and Specificity in Myasthenia Gravis a , 1987, Annals of the New York Academy of Sciences.
[166] A. Engel,et al. Lambert‐Eaton myasthenic syndrome: II. Immunoelectron microscopy localization of IgG at the mouse motor end‐plate , 1987, Annals of neurology.
[167] R. Aalberse,et al. Inhibition of complement activation by IgG4 antibodies. , 1986, Clinical and experimental immunology.
[168] P. Whiting,et al. Myasthenia gravis , 1986, Neurology.
[169] A. Engel,et al. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[170] J. Newsom-Davis,et al. Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse. , 1983, The Journal of physiology.
[171] A. Vincent,et al. Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis , 1983, Neurology.
[172] G. Scadding,et al. Acetylcholine receptor antibody synthesis by thymic lymphocytes , 1981, Neurology.
[173] P. Berman,et al. Linkage between the frequency of muscular weakness and loci that regulate immune responsiveness in murine experimental myasthenia gravis , 1980, The Journal of experimental medicine.
[174] A. Vincent,et al. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. , 1980, Brain : a journal of neurology.
[175] A. Vincent,et al. Anti-acetylcholine receptor antibodies. , 1980, Journal of neurology, neurosurgery, and psychiatry.
[176] J. Lindstrom,et al. Antigenic modulation and receptor loss in experimental autoimmune myasthenia gravis , 1979, Muscle & nerve.
[177] J. Michelson,et al. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. , 1978, The New England journal of medicine.
[178] R. Ulevitch,et al. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis , 1978, The Journal of experimental medicine.
[179] C. Hawkey,et al. [Plasmapheresis for myasthenia gravis]. , 1978, The New England journal of medicine.
[180] G. Scadding,et al. IN-VITRO SYNTHESIS OF ANTI-ACETYLCHOLINE-RECEPTOR ANTIBODY BY THYMIC LYMPHOCYTES IN MYASTHENIA GRAVIS , 1978, The Lancet.
[181] A. Engel,et al. ULTRASTRUCTURAL LOCALIZATION OF IMMUNE COMPLEXES (IgG and C3) AT THE END‐PLATE IN EXPERIMENTAL AUTOMMUNE MYASTHENIA GRAVIS , 1977, Journal of neuropathology and experimental neurology.
[182] A. Engel,et al. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. , 1977, Mayo Clinic proceedings.
[183] J. Lindstrom,et al. Antibody to acetylcholine receptor in myasthenia gravis , 1976, Neurology.
[184] A. Pestronk,et al. Myasthenia gravis: passive transfer from man to mouse , 1975, Science.
[185] D. Drachman,et al. Neuromuscular Junction in Myasthenia Gravis: Decreased Acetylcholine Receptors , 1973, Science.
[186] J. Patrick,et al. Autoimmune Response to Acetylcholine Receptor , 1973, Science.
[187] W. W. Hofmann,et al. An electrophysiological investigation of neuro‐muscular transmission in myasthenia gravis , 1964, The Journal of physiology.
[188] J. Simpson. Myasthenia Gravis: A New Hypothesis , 1960 .
[189] M. Walker. TREATMENT OF MYASTHENIA GRAVIS WITH PHYSOSTIGMINE , 1934 .
[190] J. Goldstein,et al. Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody–Positive Myasthenia Gravis , 2017, JAMA neurology.
[191] G. Plant,et al. Ocular Myasthenia Gravis: Controversies and Updates , 2013, Current Neurology and Neuroscience Reports.
[192] A. Mamalaki,et al. The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies , 2008, Molecular Neurobiology.
[193] A. Marx,et al. Immunopathology and Infectious Disease Myasthenia Gravis Thymus Complement Vulnerability of Epithelial and Myoid Cells , Complement Attack on Them , and Correlations with Autoantibody Status , 2007 .
[194] R. Pirskanen,et al. Different HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis , 2005, Immunogenetics.
[195] H. Inoko,et al. Combinations of HLA-DPB1 and HLA-DQB1 alleles determine susceptibility to early-onset myasthenia gravis in Japan. , 1994, Autoimmunity.
[196] S. Gammeltoft,et al. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. , 1987, Clinical and experimental immunology.
[197] H. Müller-Hermelink,et al. Immunohistological patterns of non-neoplastic changes in the thymus in Myasthenia gravis , 1986, Virchows Archiv. B, Cell pathology including molecular pathology.
[198] N. Murray,et al. Lambert-Eaton myasthenic syndrome: electrophysiological evidence for a humoral factor. , 1982, Muscle & nerve.
[199] C. Cardwell,et al. A systematic review of population based epidemiological studies in Myasthenia Gravis , 2010, BMC neurology.